Hide messageView More

Coronavirus (COVID-19) Health and Safety Guide

ASERT has compiled resources for those with autism and those who care for people with autism relating to the current COVID-19 outbreak.

Read More

ASD and Psychopharmacology (For Clinicians) - four 60-minute course modules (CE/CME credit available)

Login or Register to take this course.

Course Description

Health professionals serving individuals with ASD are increasingly called upon to assist in psychopharmacological treatment of interfering behaviors and other co-morbidities associated with an ASD diagnosis. Psychiatric co-morbidities that often warrant medication treatment, including depression and behavior problems (e.g., aggression and self-destructive behaviors) can increase in adolescence and adulthood. Recent reviews have described a high frequency of psychotropic medication treatment in children and adolescents with ASD, and this trend continues through adulthood. Therefore, the professional practice performance gap or quality gap that needs to be addressed is health-professional knowledge in the treatment of individuals with ASD using a multidisciplinary approach including medication management coupled with behavioral interventions and data collection.

The CME and CE activity includes four web-based interviews with a series of physician experts on autism spectrum disorder (ASD) on psychopharmacological interventions for individuals with ASD. The goal of this CME activity is to increase health care professional knowledge and performance in serving individuals with autism spectrum disorders through education regarding psychopharmacological interventions.

Course Objectives

  • Recognize and diagnose ASD in adulthood and assess the need for medication for individuals with ASD.
  • Associate ADHD and OCD symptoms in individuals with ASD with medication.
  • Define ways to treat social anxiety and other social difficulties in individuals with ASD medications and other interventions.
  • Identify dimensions of behaviors in individuals with ASD and coordinating medication management with behavioral treatment.

Course Details

There are four modules or lessons in the ASD and Psychopharmacology Continuing Education course. Each lesson takes one hour and qualifies for 1 AMA PRA Category 1 Credit(s)TM. Following each module, you will have one week to complete the linked post-test and evaluation with a score of 80 percent or higher on the post-test. After completing the evaluation, you will receive an emailed certificate within 7 business days.

To successfully complete each activity and receive credit:

  • Review the learning objectives.
  • Review the online enduring material.
  • Complete the online post-test. Participants must receive a test score of 80 percent.
  • Complete the activity evaluation.

Continuing Medical Education Credit Statements

CME: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Drexel University College of Medicine and the A.J. Drexel Autism Institute. The Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA: The Drexel University College of Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AOA: This program is eligible for 4 credits in Category 2A of the American Osteopathic Association.

Disclosure Statement: It is the policy of Drexel University College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients). Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.